Tam VH, Cohen DN, Ledesma KR, Guillory B, Chan K, Garey KW. Local Tissue Response to Subcutaneous Administration of Ceftriaxone in an Animal Model. Antimicrob Agents Chemother. 2020 Feb 21;64(3). pii: e02090-19. doi: 10.1128/AAC.02090-19. Print 2020 Feb 21.

Xie LX, Zhou J, Ledesma KR, Merlau PR, Tam VH. The impact of serum protein binding on bacterial killing of minocycline. J Glob Antimicrob Resist. 2019 Nov 23. pii: S2213-7165(19)30303-0. doi: 10.1016/j.jgar.2019.11.011.

Abodakpi H, Wanger A, Tam VH. What the Clinical Microbiologist Should Know About Pharmacokinetics/Pharmacodynamics in the Era of Emerging Multidrug Resistance: Focusing on β-Lactam/β-Lactamase Inhibitor Combinations. Clin Lab Med. 2019 Sep;39(3):473-485. doi: 10.1016/j.cll.2019.05.006. Epub 2019 Jul 6. Review.

Pogue JM, Tam VH. Toxicity in Patients. Adv Exp Med Biol. 2019;1145:289-304. doi: 10.1007/978-3-030-16373-0_17. Review.

Bulitta JB, Hope WW, Eakin AE, Guina T, Tam VH, Louie A, Drusano GL, Hoover JL. Generating Robust and Informative Nonclinical In Vitro and In Vivo Bacterial Infection Model Efficacy Data To Support Translation to Humans. Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii: e02307-18. doi: 10.1128/AAC.02307-18. Print 2019 May. Review. PMID: 30833428

Tsuji BT, Pogue JM, Zavascki AP, Paul M, Daikos GL, Forrest A, Giacobbe DR, Viscoli C, Giamarellou H, Karaiskos I, Kaye D, Mouton JW, Tam VH, Thamlikitkul V, Wunderink RG, Li J, Nation RL, Kaye KS. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019 Jan;39(1):10-39. doi: 10.1002/phar.2209 PMID: 30710469

Skoglund E, Abodakpi H, Rios R, Diaz L, De La Cadena E, Dinh AQ, Ardila J, Miller WR, Munita JM, Arias CA, Tam VH, Tran TT. In Vivo Resistance to Ceftolozane/Tazobactam in Pseudomonas aeruginosa Arising by AmpC- and Non-AmpC-Mediated Pathways. Case Rep Infect Dis. 2018 Dec 23;2018:9095203. doi: 10.1155/2018/9095203. eCollection 2018. PMID: 30675406

Abodakpi H, Chang KT, Zhou J, Byerly C, Tam VH. A novel framework to compare the effectiveness of β-lactamase inhibitors against extended-spectrum β-lactamase-producing Enterobacteriaceae. Clin Microbiol Infect. 2019 Jan 18. pii: S1198-743X(19)30007-2. doi: 10.1016/j.cmi.2019.01.003. [Epub ahead of print] PMID: 30664934

Phe K, Bowers DR, Babic JT, Tam VH. Outcomes of empiric aminoglycoside monotherapy for Pseudomonas aeruginosa bacteremia. Diagn Microbiol Infect Dis. 2019 Apr;93(4):346-348. doi: 10.1016/j.diagmicrobio.2018.10.019. Epub 2018 Nov 9. PMID: 30522794

Abodakpi H, Chang KT, Gao S, Sánchez-Díaz AM, Cantón R, Tam VH. Optimal Piperacillin-Tazobactam Dosing Strategies against Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae. Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e01906-18. doi: 10.1128/AAC.01906-18. Print 2019 Feb. PMID: 30530606

Manchandani P, Thamlikitkul V, Dubrovskaya Y, Babic JT, Lye DC, Lee LS, Tam VH. Population pharmacokinetics of polymyxin B. Clin Pharmacol Ther 2018; 104(3): 534-8

Tam VH, Pérez C, Ledesma KR, Lewis RE. Transcriptional profiles of the pulmonary innate immune response to isogenic antibiotic-susceptible and multidrug-resistant Pseudomonas aeruginosa. Microbiol Immunol 2018; 62(4): 291-4

Abodakpi H, Chang KT, Sánchez-Díaz AM, Cantón R, Lasco TM, Chan K, Sofjan AK, Tam VH. Prevalence of extended-spectrum beta-lactamase and carbapenemase-producing bloodstream isolates of Klebsiella pneumoniae in a tertiary care hospital. J Chemother 2018; 30(2): 115-9

Skoglund E, Ledesma KR, Lasco TM, Tam VH. Ceftolozane-tazobactam activity against meropenem non-susceptible Pseudomonas aeruginosa bloodstream infection isolates. J Glob Antimicrob Resist 2017; 11: 154-5

Babic JT, Manchandani P, Ledesma KR, Tam VH. Evaluation of urinary KIM-1 for prediction of polymyxin B-induced nephrotoxicity. Antimicrob Agents Chemother 2017; 61(11): e01735-17

Grossman TH, Christ D, Gooldy M, Henning LN, Heine HS, Kindt V, Lin W, Siefkas-Patterson K, Radcliff AK, Tam VH, Sutcliffe JA. The fluorocycline TP-271 is efficacious in models of aerosolized Francisella tularensis SCHU S4 infection in BALB/c mice and cynomolgus macaques. Antimicrob Agents Chemother 2017; 61(8): e00448-17

Singh KV, Tran TT, Nannini EC, Tam VH, Arias CA, Murray BE. Efficacy of ceftaroline in a rat model of endocarditis against methicillin-susceptible Staphylococcus aureus exhibiting the cefazolin high inoculum effect. Antimicrob Agents Chemother 2017; 61(7): e00324-17

Tängdén T, Ramos Martín V, Felton TW, Nielsen EI, Marchand S, Brüggemann RJ, Bulitta JB, Bassetti M, Theuretzbacher U, Tsuji BT, Wareham DW, Friberg LE, De Waele JJ, Tam VH, Roberts JA. The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections. Intensive Care Med 2017; 43(7): 1021-32

Tran TT, Tam VH, Murray BE, Arias CA, Singh KV. Efficacy of telavancin alone and in combination with ampicillin in a rat model of Enterococcus faecalis endocarditis. Antimicrob Agents Chemother 2017; 61(6): e02489-16

Zhou J, Ledesma KR, Chang KT, Abodakpi H, Tam VH. Pharmacokinetics and pharmacodynamics of minocycline against Acinetobacter baumannii in a neutropenic murine pneumonia model. Antimicrob Agents Chemother 2017; 61(5): e02371-16

Zhou J, Tran BT, Tam VH. The complexity of minocycline serum protein binding. J Antimicrob Chemother 2017; 72(6): 1632–4

Manchandani P, Zhou J, Babic JT, Ledesma KR, Truong LD, Tam VH. Role of renal drug exposure in polymyxin B-induced nephrotoxicity. Antimicrob Agents Chemother 2017; 61 (4): e02391-16

Tam VH, Chang KT, Zhou J, Ledesma KR, Phe K, Gao S, Van Bambeke F, Sánchez-Díaz AM, Zamorano L, Oliver A, Cantón R. Determining beta-lactam exposure threshold to suppress resistance development in Gram-negative bacteria. J Antimicrob Chemother 2017 ; 72(5): 1421-1428

Trad MA, Zhong LH, Lloirn RM, Tan SY, Chan M, Archuleta S, Sulaiman Z, Tam VH, Lye DC, Fisher DA. Ertapenem in outpatient parenteral antimicrobial therapy for complicated urinary tract infections. J Chemother 2017; 29(1): 25-9

Thamlikitkul V, Dubrovskaya Y, Manchandani P, Ngamprasertchai T, Boonyasiri A, Babic JT, Tam VH. Dosing and pharmacokinetics of polymyxin B in renal insufficiency. Antimicrob Agents Chemother 2017; 61 (1): e01337-16

Phe K, Shields RK, Tverdek FP, Aitken SL, Guervil DJ, Lam WM, Musgrove RJ, Luce AM, Tam VH. Predicting the risk of nephrotoxicity in patients receiving colistimethate sodium: a multicenter, retrospective, cohort study. J Antimicrob Chemother 2016; 71 (12): 3585-7

Manchandani P, Dubrovskaya Y, Gao S, Tam VH. Comparative pharmacokinetic profiling of different polymyxin B components. Antimicrob Agents Chemother 2016; 60(11): 6980-2

Cao H, Phe K, Laine GA, Russo HR, Putney KS, Tam VH. An institutional review of antimicrobial stewardship interventions. J Glob Antimicrob Resist 2016; 6: 75-7

Aitken SL, Zhou J, Ghantoji SS, Kontoyiannis DP, Jones RB, Tam VH, Chemaly RF. Pharmacokinetics and safety of intravesicular cidofovir in allogeneic hematopoietic stem cell transplant recipients. J Antimicrob Chemother 2016; 71 (3): 727-30

Patel TS, Cottreau JM, Hirsch EB, Tam VH. Impact of hyperglycemia on outcomes of patients with Pseudomonas aeruginosa bacteremia. Diagn Microbiol Infect Dis 2016; 84(2): 155-8

Manchandani P, Zhou J, Ledesma KR, Truong LD, Chow DS, Eriksen JL, Tam VH. Characterization of polymyxin B bio-distribution and disposition in an animal model. Antimicrob Agents Chemother 2016; 60(2): 1029-34

Zhang D, Wu L, Chow DS, Tam VH, Rios DR. Quantitative determination of dopamine in human plasma by a highly sensitive LC-MS/MS assay: application in preterm neonates. J Pharm Biomed Anal 2016; 117: 227-31

Abodakpi H, Gohlke J, Chang KT, Chow DS, Tam VH. Analytical and functional determination of polymyxin B protein binding in serum. Antimicrob Agents Chemother 2015; 59 (11): 7121-3

Bhagunde PR, Tam VH, Nikolaou M. Modeling heterogeneous bacterial populations exposed to antibiotics: the logistic-dynamics case. AICHE J 2015; 61: 2385–93

Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH. Risk factors for nephrotoxicity onset associated with polymyxin B therapy. J Antimicrob Chemother 2015; 70(6): 1903-7

Aitken SL, Altshuler J, Guervil DJ, Hirsch EB, Ostrosky-Zeichner LL, Ericsson CD, Tam VH. Cefepime free minimum concentration to minimum inhibitory concentration (fCmin/MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia. Int J Antimicrob Agents 2015; 45(5): 541-4

Tam VH, Ledesma KR, Bowers DR, Zhou J, Truong LD. Kidney injury associated with telavancin dosing regimen in an animal model. Antimicrob Agents Chemother 2015; 59(5): 2930-3

Bowers DR, Cao H, Zhou J, Ledesma KR, Sun D, Lomovskaya O, Tam VH. Assessment of minocycline and polymyxin B combination against Acinetobacter baumannii. Antimicrob Agents Chemother 2015; 59(5): 2720-5

Nation RL, Li J, Cars O, Couet W, Dudley MN, Kaye KS, Mouton JW, Paterson DL, Tam VH, Theuretzbacher U, Tsuji BT, Turnidge JD. The Prato polymyxin consensus: recommendations arising from the 1st international conference on polymyxins. Lancet Infect Dis 2015; 15(2): 225-34

Phe K, Dao D, Palmer HR, Tam VH. In vitro ceftriaxone susceptibility in methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother 2015; 59(2): 1370

Zasowski E, Bland CM, Tam VH, Lodise TP. Identification of optimal renal dosage adjustments for high dose extended-infusion cefepime dosing regimens in hospitalized patients. J Antimicrob Chemother 2015; 70(3): 877-81

Bernhardt MB, Moffett BS, Johnson M, Tam VH, Thompson P, Garey KW. Agreement among measurements and estimations of glomerular filtration in children with cancer. Pediatr Blood Cancer 2015; 62(1): 80-4

Phe K, Johnson ML, Palmer HR, Tam VH. Validation of a model to predict the risk of nephrotoxicity in patients receiving colistin. Antimicrob Agents Chemother 2014; 58 (11): 6946-8

Zhang D, Rios DR, Tam VH, Chow DSL. Development and validation of a highly sensitive LC-MS/MS assay for the quantification of arginine vasopressin in human plasma and urine: application in preterm neonates and child. J Pharm Biomed Anal 2014; 99: 67-73

Tan MW, Lye DC, Ng TM, Nikolaou M, Tam VH. Mathematical model to quantify the effects of risk factors on carbapenem resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2014; 58(9): 5239-44

Zhou J, Sulaiman Z, Llorin RM, Hee KH, Lee LS, Lye DC, Fisher DA, Tam VH. Pharmacokinetics of ertapenem in outpatients with complicated urinary tract infections. J Antimicrob Chemother 2014; 69(9): 2517-21

Abdelraouf K, Chang KT, Yin T, Hu M, Tam VH. Uptake of polymyxin B into renal cells. Antimicrob Agents Chemother 2014; 58(7): 4200-2

Phe K, Lee Y, McDaneld PM, Prasad N, Yin T, Figueroa DA, Musick WL, Cottreau JM, Hu M, Tam VH. In vitro assessment and multicenter cohort study of comparison of nephrotoxicity rates associated with colistimethate versus polymyxin B therapy. Antimicrob Agents Chemother 2014; 58(5): 2740-6

Bowers DR, Kainer LL, Mai KA, Tam VH. An objective assessment of professional pharmacy programmes in the United States. Pharmacy Education 2014; 14 (1): 16-20

Hirsch EB, Chang KT, Zucchi PC, Francoeur DN, Ledesma KR, Tam VH, Lasco TM. An evaluation of multiple phenotypic screening methods for Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae. J Infect Chemother 2014; 20 (3): 224-7

Ng TM, Lye DC, Chan M, Tam VH.  Predictive performance of pharmacokinetic models for outpatients receiving vancomycin continuous infusion. Int J Antimicrob Agents 2014; 43(2): 197-9

Nation RL, Li J, Cars O, Couet W, Dudley MN, Kaye KS, Mouton JW, Paterson DL, Tam VH, Theuretzbacher U, Tsuji BT, Turnidge JD. Consistent global approach on reporting of colistin doses to promote safe and effective use. Clin Infect Dis 2014; 58(1): 139-41

He J, Abdelraouf K, Ledesma KR, Chow DSL, Tam VH. Pharmacokinetics and efficacy of liposomal polymyxin B in a murine pneumonia model. Int J Antimicrob Agents 2013; 42(6): 559-64

Bowers DR, Tam VH. Pseudomonas aeruginosa treatment and transmission reduction. Expert Rev Anti Infect Ther 2013; 11(8): 831-7

He J, Gao S, Hu M, Chow DS, Tam VH. A validated UPLC-MS/MS method for the quantification of polymyxin B in mouse serum and epithelial lining fluid: application to pharmacokinetic studies. J Antimicrob Chemother 2013; 68(5): 1104-10

Bowers DR, Liew YX, Lye DC, Kwa AL, Hsu LY, Tam VH. Outcome of appropriate empiric combination versus monotherapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 2013; 57(3): 1270-4

Hirsch EB, Guo B, Chang KT, Cao H, Ledesma KR, Singh M, Tam VH. Assessment of antimicrobial combinations for KPC-producing Klebsiella pneumoniae. J Infect Dis 2013; 207 (5): 786-93

Tam VH, Chang KT, Yang Z, Newman J, Hu M. In vitro pharmacodynamics of AZD5206 against Staphylococcus aureus. Antimicrob Agents Chemother 2013; 57(2): 1062-4

Abdelraouf K, He J, Ledesma KR, Hu M, Tam VH. Pharmacokinetics and renal disposition of polymyxin B in an animal model. Antimicrob Agents Chemother 2012; 56(11): 5724-7

Verrall AJ, Llorin R, Tam VH, Lye DC, Sulaiman Z, Zhong L, Archuleta S, Fisher DA. Efficacy of continuous infusion of vancomycin for the outpatient treatment of methicillin-resistant Staphylococcus aureus infections. J Antimicrob Chemother 2012; 67(12): 2970-3

Abdelraouf K, Braggs KH, Yin T, Truong LD, Hu M, Tam VH. Characterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen design. Antimicrob Agents Chemother 2012; 56(9): 4625-9

Belden VS, Hirsch EB, Halfon R, Sirimaturos M, Nguyen PT, Singh R, Liebl MG, Tam VH. Pharmacokinetics of cefepime in critically-ill patients undergoing continuous renal replacement therapy.  TSHP J 2012; 13(2): 5-10 

Tam VH, Hirsch EB, Lasco TM, Gentry LO, Palmer HR. Correlation of hospital carbapenem consumption and resistance trends in selected Gram-negative bacteria. Ann Pharmacother 2012; 46(7-8): 1120-2

Hirsch EB, Ledesma KR, Chang KT, Schwartz MS, Motyl MR, Tam VH. In vitro activity of MK-7655, a novel beta-lactamase inhibitor, in combination with imipenem against carbapenem resistant Gram-negative bacteria. Antimicrob Agents Chemother 2012; 56(7): 3753-7

Tiong CT, Chen C, Zhang SJ, Li J, Soshilov A, Denison MS, Lee Soon-U L, Tam VH, Wong SP, Xu HE, Yong EL. A novel prenylflavone restricts breast cancer cell growth through AhR-mediated destabilization of ERα protein. Carcinogenesis 2012; 33(5): 1089-97

Tran TT, Palmer HP, Weston J, Hirsch EB, Shah DN, Cottreau J, Tam VH, Garey KW. Evaluation of a daptomycin dose optimization protocol: a potential policy for antibiotic stewardship programs. Am J Health Syst Pharm 2012; 69(11): 979-84

Bhagunde P, Chang KT, Hirsch EB, Ledesma KR, Nikolaou M, Tam VH. A novel modeling framework to guide design of optimal dosing strategies for beta-lactamase inhibitors. Antimicrob Agents Chemother 2012; 56(5): 2237-40

Singh R, Swick MC, Ledesma KR, Yang Z, Hu M, Zechiedrich L, Tam VH. Temporal interplay between efflux pumps and target mutations in development of antibiotic resistance in Escherichia coli. Antimicrob Agents Chemother 2012; 56(4): 1680-5

Guo B, Abdelraouf K, Ledesma KR, Nikolaou M, Tam VH. Predicting bacterial fitness cost associated with drug resistance. J Antimicrob Chemother 2012; 67(4): 921-7

Hirsch EB, Cottreau JM, Chang KT, Caeiro JP, Johnson ML, Tam VH. A model to predict mortality following Pseudomonas aeruginosa bacteremia. Diagn Microbiol Infect Dis. 2012 Jan;72(1):97-102.

Palmer HR, Weston J, Gentry L, Salazar M, Putney K, Frost C, Tipton JA, Cottreau J, Tam VH, Garey KW. Improving patient care through implementation of an antimicrobial stewardship program. Am J Health Syst Pharm. 2011 Nov 15;68(22):2170-4.

Singh R, Tam VH. Optimizing dosage to prevent emergence of resistance - lessons from in vitro models. Curr Opin Pharmacol. 2011 Oct;11(5):453-6.

Guo B, Abdelraouf K, Ledesma KR, Chang KT, Nikolaou M, Tam VH. Quantitative impact of neutrophils on bacterial clearance in a murine pneumonia model. Antimicrob Agents Chemother. 2011 Oct;55(10):4601-5.

Tam VH, Cao H, Ledesma KR, Hu M. In-vitro potency of various polymyxin B components. Antimicrob Agents Chemother 2011; 55(9): 4490-1

Abdelraouf K, Kabbara S, Ledesma KR, Poole K, Tam VH. Effect of multidrug resistance-conferring mutations on the biofitness and virulence of Pseudomonas aeruginosa. J Antimicrob Chemother 2011; 66(6): 1311-7

Bhagunde P, Singh R, Ledesma KR, Chang KT, Nikolaou M, Tam VH. Modeling biphasic killing of fluoroquinolones: optimal design of dosing regimens. J Antimicrob Chemother 2011; 66(5): 1079-86

Kwa AL, Abdelraouf K, Low JGH, Tam VH. Pharmacokinetics of polymyxin B in a patient with renal insufficiency: a case report. Clin Infect Dis 2011; 52(10): 1280-1

Kwa AL, Falagas ME, Michalopoulos A, Tam VH. Benefits of aerosolized colistin for ventilator associated pneumonia: absence of proof versus proof of absence? Clin Infect Dis 2011; 52(10): 1278-9

Salvatore CM, Abdelraouf K, Hsing DD, Tam VH. Pharmacokinetics of polymyxin B in an infant with multi-drug resistant Klebsiella pneumoniae. Pediatr Infect Dis J 2011; 30(6): 537-9

Tam VH, Nikolaou M. A novel approach to pharmacodynamic characterization of antimicrobial agents: new insights to dosing regimen design. PLoS Comput Biol 2011; 7(1): e1001043

Hirsch EB, Chang KT, Lasco TM, Caeiro JP, Tam VH. Emergence of KPC-producing Klebsiella pneumoniae in Texas. Diagn Microbiol Infect Dis 2011; 69(2): 234-5